<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia - Adelufosi, AO - 2015 | Cochrane Library</title> <meta content="Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia - Adelufosi, AO - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010501.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia - Adelufosi, AO - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010501.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010501.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia" name="citation_title"/> <meta content="Adegoke Oloruntoba Adelufosi" name="citation_author"/> <meta content="Northern Regional Health Authority" name="citation_author_institution"/> <meta content="ozotee@gmail.com" name="citation_author_email"/> <meta content="Olukayode Abayomi" name="citation_author"/> <meta content="Ladoke Akintola University Teaching Hospital" name="citation_author_institution"/> <meta content="Tunde Massey‐Ferguson Ojo" name="citation_author"/> <meta content="Neuropsychiatric Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD010501.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/04/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010501.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010501.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010501.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*adverse effects]; Dyskinesia, Drug‐Induced [*drug therapy, etiology]; Pyridoxal Phosphate [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [drug therapy]; Vitamin B Complex [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010501.pub2&amp;doi=10.1002/14651858.CD010501.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010501\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010501\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010501.pub2",title:"Pyridoxal 5 phosphate for neuroleptic\\u2010induced tardive dyskinesia",firstPublishedDate:"Apr 13, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010501.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010501.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010501.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010501.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010501.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010501.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010501.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010501.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010501.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010501.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1829 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010501.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0127"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0088"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-sec-0121"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/table_n/CD010501StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/table_n/CD010501StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#CD010501-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Adegoke Oloruntoba Adelufosi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#CD010501-cr-0003">Olukayode Abayomi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information#CD010501-cr-0004">Tunde Massey‐Ferguson Ojo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information/en#CD010501-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 April 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010501.pub2">https://doi.org/10.1002/14651858.CD010501.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010501-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010501-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010501-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010501-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010501-abs-0001" lang="en"> <section id="CD010501-sec-0001"> <h3 class="title" id="CD010501-sec-0001">Background</h3> <p>Tardive dyskinesia is a chronic and disabling abnormal movement disorder affecting the muscles of the face, neck, tongue and the limbs. It is a common side effect of long‐term antipsychotic medication use in individuals with schizophrenia and other related psychotic disorders. While there are no known effective treatments for tardive dyskinesia to date, some reports suggest that pyridoxal 5 phosphate may be effective in reducing the severity of tardive dyskinesia symptoms. </p> </section> <section id="CD010501-sec-0002"> <h3 class="title" id="CD010501-sec-0002">Objectives</h3> <p>To determine the effectiveness of pyridoxal 5 phosphate (vitamin B6 or Pyridoxine or Pyridoxal phosphate) in the treatment of neuroleptic‐induced tardive dyskinesia among people with schizophrenia and other related psychotic disorders. </p> </section> <section id="CD010501-sec-0003"> <h3 class="title" id="CD010501-sec-0003">Search methods</h3> <p>The Cochrane schizophrenia group's register of clinical trials was searched (January 2013) using the phrase: [*Pyridoxal* OR *Pyridoxine* OR *P5P* OR *PLP* OR *tardoxal* OR *Vitamin B6* O *Vitamin B 6* R in title, abstract or index terms of REFERENCE, or interventions of STUDY. References of relevant identified studies were handsearched and where necessary, the first authors of relevant studies were contacted. </p> </section> <section id="CD010501-sec-0004"> <h3 class="title" id="CD010501-sec-0004">Selection criteria</h3> <p>Studies described as randomised controlled trials comparing the effectiveness pyridoxal 5 phosphate with placebo in the treatment of neuroleptic‐induced tardive dyskinesia among patients with schizophrenia. </p> </section> <section id="CD010501-sec-0005"> <h3 class="title" id="CD010501-sec-0005">Data collection and analysis</h3> <p>The review authors independently extracted data from each selected study. For dichotomous data, we calculated risk ratios (RR) and their 95% confidence intervals (CIs) on an intention‐to‐treat basis based on a fixed‐effect model. For continuous data, we calculated mean differences (MD) with 95% CIs, again based on a fixed‐effect model. We assessed risk of bias for each included study and used GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to rate quality of evidence. </p> </section> <section id="CD010501-sec-0006"> <h3 class="title" id="CD010501-sec-0006">Main results</h3> <p>Of the 12 records retrieved by the search, three trials published in 2001, 2003 and 2007, involving 80 inpatients with schizophrenia, aged 18 to 71 years, admitted in a psychiatric facility and followed up for a period nine weeks to 26 weeks, were included. Overall, pyridoxal 5 phosphate produced a significant improvement in tardive dyskinesia symptoms when compared with placebo, assessed by a change in Extrapyramidal Symptoms Rating Scale (ESRS) scores from baseline to the end of the first phase of the included studies (2 RCTs n = 65, RR 19.97, CI 2.87 to 139.19, <i>low quality evidence</i> ). The endpoint tardive dyskinesia score (a measure of its severity) assessed with the ESRS, was significantly lower among participants on pyridoxal 5 phosphate compared to those on placebo (2 RCTs n = 60, MD ‐4.07, CI ‐6.36 to ‐1.79, <i>low quality evidence</i>). </p> <p>It was unclear whether pyridoxal 5 phosphate led to more side effects (n = 65, 2 RCTs, RR 3.97, CI 0.20 to 78.59, <i>low quality evidence)</i> or caused deterioration in tardive dyskinesia symptoms when compared to placebo (n = 65, 2 RCTs, RR 0.16, CI 0.01 to 3.14, <i>low quality evidence</i> ). Five participants taking pyridoxal 5 phosphate withdrew from the study because they were not willing to take more medications while none of the participants taking placebo discontinued their medications (n = 65, 2 RCTs, RR 8.72, CI 0.51 to 149.75, <i>low quality evidence</i>). </p> <p>There was no significant difference in the endpoint positive and negative psychiatric symptoms scores, measured using the Positive and Negative symptoms Scale (PANSS) between participants taking pyridoxal 5 phosphate and those taking placebo. For the positive symptoms: (n = 15, 1 RCT, MD ‐1.50, CI ‐4.80 to 1.80, <i>low quality evidence)</i> . For negative the symptoms: (n = 15, 1 RCT, MD ‐1.10, CI ‐5.92 to 3.72, <i>low quality evidence</i>). </p> </section> <section id="CD010501-sec-0007"> <h3 class="title" id="CD010501-sec-0007">Authors' conclusions</h3> <p>Pyridoxal 5 phosphate may have some benefits in reducing the severity of tardive dyskinesia symptoms among individuals with schizophrenia. However, the quality of evidence supporting the effectiveness of pyridoxal 5 phosphate in treating tardive dyskinesia is low, based on few studies, short follow‐up periods, small sample sizes and inadequate adherence to standardised reporting guidelines for randomised controlled trials among the included studies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010501-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010501-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010501-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010501-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010501-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010501-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010501-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010501-abs-0003" lang="en"> <h3>Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia.</h3> <p><b>Review question</b>. </p> <p>To look at the effects of pyridoxal 5 phosphate in the treatment of the movement disorder tardive dyskinesia, which is caused by long term use of antipsychotic drugs in people with schizophrenia. </p> <p><b>Background</b>. </p> <p>The main treatment for schizophrenia is antipsychotic drugs. However, these drugs sometimes have severe and disabling side effects. Tardive dyskinesia is a movement disorder that causes the muscles of the face, neck, tongue and limbs to twitch. It can be caused by taking antipsychotic drugs over a long period of time. It often results in stigma, low quality of life and can lead to people stopping their antipsychotic medication. While there are no known treatments for tardive dyskinesia, some reports suggest that pyridoxal 5 phosphate may reduce tardive dyskinesia. </p> <p><b>Study characteristics</b>. </p> <p>A search for relevant randomised studies was conducted in January 2013. The review includes three studies with 80 participants. All participants had tardive dyskinesia as a result of taking antipsychotic medication and were randomised into treatment groups. One group received pyridoxal 5 phosphate, the other group received a placebo. Antipsychotic treatment continued as usual throughout the trials. </p> <p><b>Key results</b>. </p> <p>People taking pyridoxal 5 phosphate in these studies experienced more than 40% improvement in their tardive dyskinesia compared to those on placebo, so had less severe tardive dyskinesia. Experience of side effects were similar between treatment groups with participants taking pyridoxal 5 phosphate experiencing no more or less side effects than participants in the placebo group and they did not experience greater worsening of their psychiatric symptoms than those on placebo. Evidence from the studies is weak, but suggests pyridoxal 5 phosphate may be effective in the treatment of tardive dyskinesia. </p> <p><b>Quality of the evidence</b>. </p> <p>Evidence is weak. The number of studies and participants is few. The quality of studies is low. Better evidence could be gathered by better designed, conducted and reported trials. </p> <p>Ben Gray, Senior Peer Researcher, McPin Foundation. <a href="http://mcpin.org/" target="_blank">http://mcpin.org/</a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010501-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010501-sec-0127"></div> <h3 class="title" id="CD010501-sec-0128">Implications for practice</h3> <section id="CD010501-sec-0128"> <section id="CD010501-sec-0129"> <h5 class="title">1. For individuals with tardive dyskinesia</h5> <p>Pyridoxal 5 phosphate (vitamin B6) may help in alleviating the symptoms of tardive dyskinesia for those people with schizophrenia. Vitamin B6 was not significantly associated with a worsening of tardive dyskinesia symptoms or increased occurrence of other adverse effects, when compared with placebo. <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a> reported that high doses of vitamin B6 (up to1200 mg/day) is safe and acts for up to eight weeks after cessation of treatment. However, available data in support of these conclusions about the efficacy of vitamin B6 are weak and require larger studies in the future for validation. </p> </section> <section id="CD010501-sec-0130"> <h5 class="title">2. For clinicians</h5> <p>Pyridoxal 5 phosphate (vitamin B6) may be considered in the treatment of tardive dyskinesia though the evidence supporting its effectiveness is limited. The effectiveness of vitamin B6 in treating tardive dyskinesia was noticed at doses from 300 mg daily (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>). Vitamin B6 dose as high as 1200 mg daily was given in one of the studies included in this review (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>) with only two participants experiencing side effects (acne and light itch) after two months of treatment. Therefore, given its safety and tolerability, clinicians might consider vitamin B6 as add on to antipsychotic medications. What is not clear however, is if other side effects are likely to develop when pyridoxal phosphate is used for a duration longer than that used in the included studies. </p> </section> <section id="CD010501-sec-0131"> <h5 class="title">3. For policy makers and funders of studies</h5> <p>While there are indications that pyridoxal 5 phosphate may be effective for the treatment of tardive dyskinesia, the available data supporting this conclusion are weak. In addition, the exact mechanism by which pyridoxal 5 phosphate reduces tardive dyskinesia symptoms is still unclear. </p> </section> </section> <h3 class="title" id="CD010501-sec-0132">Implications for research</h3> <section id="CD010501-sec-0132"> <section id="CD010501-sec-0133"> <h5 class="title">1. General</h5> <p>The evidence regarding the effectiveness of pyridoxal 5 phosphate in the treatment of tardive dyskinesia could be demonstrated in the future by well designed, conducted and reported randomised controlled trials (<a href="./references#CD010501-bbs2-0043" title="MoherD , SchulzKF , AltmanD , CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285:1987‐91. ">Moher 2001</a>). Other recommendations regarding the design of future trials are suggested in <a href="#CD010501-tbl-0002">Table 1</a>. </p> <div class="table" id="CD010501-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Possible design for a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: long term.<br/> Setting: Inpatients and outpatients </p> <p>Design: Single phase, longer study duration.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = Sample size obtained through power calculation.<br/> Age: any<br/> Sex: both </p> <p>History: History of tardive dyskinesia, fulfilling diagnostic criteria for tardive dyskinesia, stable on antipsychotic medication for at least 3 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Pyridoxal Phosphate (vitamin B6), any dose</p> <p>2. Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia scores measured using AIMS (primary outcome)</p> <p>Deterioration of tardive dyskinesia symptoms</p> <p>Any other adverse effects</p> <p>Discontinuation of pyridoxal phosphate (with reasons)</p> <p>Psychiatric symptoms score using a standardised rating scale (PANSS, BPRS)</p> <p>Pyridoxal phosphate dose</p> <p>Plasma pyridoxal phosphate level</p> <p>Quality of life</p> <p>Satisfaction with care</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AIMS: Abnormal Involuntary Movement Scale<br/> BPRS: Brief Psychiatric Rating Scale<br/> PANSS: Positve and Negative Scale of Schizophrenia </p> </div> </div> </section> <section id="CD010501-sec-0134"> <h5 class="title">2. Specific</h5> <section id="CD010501-sec-0135"> <h6 class="title">Use of cross‐over designs</h6> <p>Tardive dyskinesia is a chronic symptom with fluctuating course (<a href="./references#CD010501-bbs2-0015" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC1992. ">APA 1992</a>). The studies included in this review used a cross‐over study design, which is more suitable for conditions with a stable course (<a href="./references#CD010501-bbs2-0031" title="FleissJL . The crossover study. The design and analysis of clinical experiments. Chichester: John Wiley &amp; Sons1984. ">Fleiss 1984</a>). </p> </section> <section id="CD010501-sec-0136"> <h6 class="title">Sample size calculation</h6> <p>Only one of the included studies in this review used a statistical method to calculate the sample size (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). The power of future studies could be significantly improved by larger sample sizes. </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010501-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010501-sec-0015"></div> <div class="table" id="CD010501-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with neuroleptic‐induced tardive dyskinesia<br/> <b>Settings:</b> Inpatients<br/> <b>Intervention:</b> Pyridoxal 5 phosphate (vitamin B6)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pyridoxal 5 phosphate (vitamin B6) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical efficacy ‐ improvement (&gt; 40%) in ESRS scores from baseline</b> <br/> ESRS<sup>1</sup> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 19.97</b> <br/> (2.87 to 139.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global: Other adverse effects than tardive dyskinesia</b> <br/> Self‐report by participants<br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.97</b> <br/> (0.2 to 78.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global: Discontinuation of Vitamin B6</b> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 8.72</b> <br/> (0.51 to 149.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tardive dyskinesia: Deterioration in tardive dyskinesia symptoms</b> <br/> ESRS<sup>1</sup> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.16</b> <br/> (0.01 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (1 to 217) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (0 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Positive psychiatric symptom score</b> <br/> PANSS<sup>5</sup>. Scale from: 7 to 49.<br/> Follow‐up: 9 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: positive psychiatric symptom score in the control groups was<br/> <b>15.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: positive psychiatric symptom score in the intervention groups was<br/> <b>1.50 lower</b> <br/> (4.80 lower to 1.80 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Negative psychiatric symptoms</b> <br/> PANSS<sup>5</sup>. Scale from: 7 to 49.<br/> Follow‐up: 9 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: negative psychiatric symptoms in the control groups was<br/> <b>14.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: negative psychiatric symptoms in the intervention groups was<br/> <b>1.10 lower</b> <br/> (5.92 lower to 3.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Extrapyramidal Symptom Rating Scale (high scores = worse)<br/> <sup>2</sup> Study duration: 9 weeks and 26 weeks respectively for the two included studies<br/> <sup>3</sup> Adequate description of randomisation methods was not provided. Methods for allocation concealment and blinding were not described.<br/> <sup>4</sup> The included studies have small sample sizes<br/> <sup>5</sup> Positive and Negative Symptoms Scale (high scores = worse)<br/> <sup>6</sup> Study has a small sample size </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010501-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010501-sec-0016"></div> <p> </p> <section id="CD010501-sec-0017"> <h3 class="title" id="CD010501-sec-0017">Description of the condition</h3> <p>Since 1950 when the antipsychotic properties of chlorpromazine were first discovered (<a href="./references#CD010501-bbs2-0039" title="Lopez‐Munoz , AlamoC , CuencaE , ShenWW , ClervoyP , RubioG . History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry2005;17(3):113‐35. ">Lopez‐Munoz 2005</a>), antipsychotic medications have been used effectively in treating the symptoms of schizophrenia, such as hallucinations and delusions. However, one of the drawbacks of long‐term antipsychotic medication use is a disabling, potentially irreversible movement disorder called tardive dyskinesia.<br/> <br/> Tardive dyskinesia is a late onset, movement disorder often resulting from long‐term use of neuroleptic (antipsychotic) medications. It manifests as repetitive, involuntary movements affecting the face, jaw, tongue, extremities and the trunk. Abnormal movements in tardive dyskinesia may involve tongue darting, repetitive grimacing, chewing movements of the mouth, sucking movements or puckering of the lips and purposeless, irregular, jerking movements of the limbs. These symptoms are highly stigmatising and associated with poor quality of life in affected individuals (<a href="./references#CD010501-bbs2-0016" title="Ascher‐SvanumH , ZhuB , FariesD , PengX , KinonBJ , TohenM . Tardive dyskinesia and the 3‐year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry2008;69(10):1580‐8. ">Ascher‐Svanum 2008</a>; <a href="./references#CD010501-bbs2-0021" title="BrowneS , RoeM , LaneA , GervinM , MorrisM , KinsellaA , et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica1996;94:118‐24. ">Browne 1996</a>). </p> <p>Risk factors for tardive dyskinesia in patients with schizophrenia include female gender (<a href="./references#CD010501-bbs2-0057" title="YassaR , JesteDV . Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bulletin1992;18:701‐15. ">Yassa 1992</a>), older age (<a href="./references#CD010501-bbs2-0038" title="LeungSK , UngvariGS , NgFS , CheungHK , LeungT . Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. Progress in Neuropharmacology and Biological Psychiatry2003;27(6):1029‐35. ">Leung 2003</a>; <a href="./references#CD010501-bbs2-0046" title="NiehausDJH , Du PlessisSA ,  KoenL , LateganBH , Steyn J , OosthuizenPP , et al. Predictors of abnormal involuntary movement in an African schizophrenia population. Journal of Neuropsychiatry and Clinical Neurosciences2008;20:317‐26. ">Niehaus 2008</a>), cognitive impairment or neurological deficits (<a href="./references#CD010501-bbs2-0054" title="WaddingtonJL , YoussefHA , DolphinC , KinsellaA . Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Archives of General Psychiatry1987;44(10):907‐12. ">Waddington 1987</a>), diagnosis of a mood disorder especially depression (<a href="./references#CD010501-bbs2-0023" title="CaseyDE . Neuroleptic‐induced extrapyramidal syndromes and tardive dyskinesia. In: HirschS , WeinbergerDR editor(s). Schizophrenia. Oxford: Blackwell, 1995:546–65. ">Casey 1995</a>; <a href="./references#CD010501-bbs2-0036" title="KaneJ , WoernerM , BorensteinM . Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin1986;22:254–8. ">Kane 1986</a>; <a href="./references#CD010501-bbs2-0047" title="SachdevPS . Depression‐dependent exacerbation of tardive dyskinesia. British Journal of Psychiatry1989;155:253‐5. ">Sachdev 1989</a>), worsening of psychopathology (<a href="./references#CD010501-bbs2-0052" title="TenbackDE , vanHartenPN , SlooffCJ , vanOsJ , SOHO Study Group. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Comprehensive Psychiatry2007;48(5):436‐40. ">Tenback 2007</a>) and diabetes mellitus (<a href="./references#CD010501-bbs2-0023" title="CaseyDE . Neuroleptic‐induced extrapyramidal syndromes and tardive dyskinesia. In: HirschS , WeinbergerDR editor(s). Schizophrenia. Oxford: Blackwell, 1995:546–65. ">Casey 1995</a>; <a href="./references#CD010501-bbs2-0055" title="WoernerMG , SaltzBL , KaneJM , LiebermanJA , AlvirJMJ . Diabetes and development of tardive dyskinesia. American Journal of Psychiatry1993;150:966‐8. ">Woerner 1993</a>). Tardive dyskinesia is also higher among those taking first generation (conventional) antipsychotic drugs compared with those on second generation (atypical) antipsychotic medications (<a href="./references#CD010501-bbs2-0026" title="CorrellCU , SchenkEM . Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry2008;21(12):151‐6. ">Corell 2008</a>; <a href="./references#CD010501-bbs2-0044" title="NasrallahHA . Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Annals of Clinical Psychiatry2006;18(1):57‐62. ">Nasrallah 2006</a>). However, neuroleptic medications are not the sole cause of  tardive dyskinesia, as similar abnormal motor movements have been reported among patients with schizophrenia who were never exposed to neuroleptic medications (<a href="./references#CD010501-bbs2-0017" title="AyehuM , ShibreT , MilkiasB , FekaduA . Movement disorders in neuroleptic‐naïve patients with schizophrenia spectrum disorders. BMC Psychiatry2014;14:280. ">Ayehu 2014</a>; <a href="./references#CD010501-bbs2-0030" title="FentonWS . Prevalence of spontaneous dyskinesia in schizophrenia. Journal of Clinical Psychiatry2000;61(Suppl 4):10‐4. ">Fenton 2000</a>). </p> <p>The exact pathogenesis of tardive dyskinesia is unknown and several theories about its aetiology has been proposed. Foremost is the dopamine receptor supersensitivity hypothesis which posits that long‐term receptor antagonism by antipsychotic drugs results in dopamine receptor supersensitivity and the movement disorder in tardive dyskinesia (<a href="./references#CD010501-bbs2-0047" title="SachdevPS . Depression‐dependent exacerbation of tardive dyskinesia. British Journal of Psychiatry1989;155:253‐5. ">Sachdev 1989</a>; <a href="./references#CD010501-bbs2-0053" title="TeoJT , EdwardsMJ , BhatiaK . Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Movement Disorders2012;27:1205‐15. ">Teo 2012</a>). The neurotoxicity hypothesis states that tardive dyskinesia results from the neurotoxic effects of free radicals that are released during dopamine metabolism. It is believed that these free radicals cause cellular degeneration of striatal GABA‐ergic neurons, leading to the loss of their inhibitory activities and the  hyperkinetic state of tardive dyskinesia (<a href="./references#CD010501-bbs2-0047" title="SachdevPS . Depression‐dependent exacerbation of tardive dyskinesia. British Journal of Psychiatry1989;155:253‐5. ">Sachdev 1989</a>). The use of antioxidants as possible treatment for tardive dyskinesia symptoms is based on the neurotoxicity hypothesis (<a href="./references#CD010501-bbs2-0058" title="ZhangXY , ZhouDF , CaoLY , XuCQ , ChenDC , WuGY . The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double‐blind placebo‐controlled trial. Journal of Clinical Psychopharmacology2004;24:83‐6. ">Zhang 2004</a>). </p> <p>There are reports that pyridoxal 5 phosphate, a metabolite of vitamin B6 (pyridoxine) helps in alleviating these symptoms (<a href="./references#CD010501-bbs2-0042" title="MiodownikC , MeodedA , LibovI , BersudskyY , SelaB , LernerV . Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Clinical Neuropharmacology2008;31:197‐203. ">Miodownik 2008</a>). </p> </section> <section id="CD010501-sec-0018"> <h3 class="title" id="CD010501-sec-0018">Description of the intervention</h3> <p>Pyridoxal 5 phosphate is the metabolically active form of vitamin B6, a collective term for the chemically‐ and structurally‐related substances, pyridoxine, pyridoxamine and pyridoxal. Vitamin B6 is a naturally occurring vitamin that can be obtained from both animal and plant sources. Following ingestion, pyridoxine is absorbed from the upper small intestine, where it is transported to the liver and oxidised to form pyridoxal. It is then phosphorylated by pyridoxal kinase to pyridoxal 5 phosphate. Unlike pyridoxine, which causes peripheral neuropathy when high doses are given, pyridoxal 5 phosphate is not associated with any known adverse effects, even at doses as high as 1200 mg/day (<a href="./references#CD010501-bbs2-0042" title="MiodownikC , MeodedA , LibovI , BersudskyY , SelaB , LernerV . Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia. Clinical Neuropharmacology2008;31:197‐203. ">Miodownik 2008</a>; <a href="./references#CD010501-bbs2-0048" title="SchaumburgH , KaplanWA , VickN , RasmusS , PleasureD , BrownMJ . Sensory neuropathy from pyridoxine abuse ‐ A new megavitamin syndrome. New England Journal of Medicine1983;309:445‐8. ">Schaumburg 1983</a>). </p> </section> <section id="CD010501-sec-0019"> <h3 class="title" id="CD010501-sec-0019">How the intervention might work</h3> <p>Pyridoxal 5 phosphate is a coenzyme in the decarboxylation of DOPA to dopamine and other neurotransmitters such as serotonin and gamma amino butyric acid (GABA). Although its actual mechanism of action is not clear, 9t is speculated that vitamin B6 may reduce the symptoms of tardive dyskinesia through its effects on the biogenic amines, mainly dopamine, GABA, serotonin and by scavenging free radicals (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). </p> </section> <section id="CD010501-sec-0020"> <h3 class="title" id="CD010501-sec-0020">Why it is important to do this review</h3> <p>Tardive dyskinesia is very disabling and disfiguring and its occurrence is associated with poor treatment adherence (<a href="./references#CD010501-bbs2-0018" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. In: BarnesTRE editor(s). Antipsychotic Drugs and their Side‐effects. CNS and Neuromuscular Effects. Vol. I, London: Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>) and low quality of life (<a href="./references#CD010501-bbs2-0016" title="Ascher‐SvanumH , ZhuB , FariesD , PengX , KinonBJ , TohenM . Tardive dyskinesia and the 3‐year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry2008;69(10):1580‐8. ">Ascher‐Svanum 2008</a>). The reported prevalence of tardive dyskinesia ranged from 3% to 70% with a median of 24% among patients on long‐term use of neuroleptic medications (<a href="./references#CD010501-bbs2-0057" title="YassaR , JesteDV . Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bulletin1992;18:701‐15. ">Yassa 1992</a>).The annual incidence is 5.2% in those with a first episode of schizophrenia placed on neuroleptic medications, the rate increasing to about 20% at five years (<a href="./references#CD010501-bbs2-0024" title="ChakosMH , AlvirJMJ , WoernerMG , KoreenA , GeislerS , MayerhoffD , et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry1996;53:313–9. ">Chakos 1996</a>). Several drugs have been used in an attempt to treat tardive dyskinesia, but little evidence exists to support their efficacy. Such interventions include melatonin (<a href="./references#CD010501-bbs2-0045" title="Nelson , LA , McGuireJM , HausafusSN . Melatonin for the treatment of tardive dyskinesia. Annals of Pharmacotherapy2003;37:1128‐31. ">Nelson 2003</a>), cholinergic agonists (<a href="./references#CD010501-bbs2-0022" title="CaroffSN , CampbellEC , HaveyJ , SullivanKA , MannSC , GallopR . Treatment of tardive dyskinesia with donepezil: A pilot study. Journal of Clinical Psychiatry2001;62(10):772‐5. ">Caroff 2001</a>), vitamin E (<a href="./references#CD010501-bbs2-0013" title="AdlerLA , EdsonR , LavoriP , PeselowE , DuncanE , RosenthalM , et al. Long‐term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry1998;43:868‐72. ">Adler 1998</a>), calcium channel blockers (<a href="./references#CD010501-bbs2-0029" title="Fay‐McCarthyM , KendrickKA , RosseRB , SchwartzBL , PeaceT , WyattRJ , et al. The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients. Schizophrenia Research1997;24(1‐2):271. ">Fay‐McCarthy 1997</a>) and clozapine (<a href="./references#CD010501-bbs2-0019" title="BassittDP , Louzã NetoMR . Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European Archives Psychiatry and Clinical Neuroscience1998;248(4):209‐11. ">Bassitt 1998</a>). While the evidence for the effectiveness for some of these interventions has been evaluated (<a href="./references#CD010501-bbs2-0041" title="McGrathJ , Soares‐WeiserK . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD000209] ">McGrath 2001</a>; <a href="./references#CD010501-bbs2-0050" title="Soares‐WeiserK , RathboneJ . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000206.pub2] ">Soares‐Weiser 2004</a>; <a href="./references#CD010501-bbs2-0051" title="TammenmaaI , McGrathJ , SailasEES , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207] ">Tammenmaa 2002</a>), no evaluation has taken place for pyridoxal 5 phosphate. Thus, it is uncertain if pyridoxal 5 phosphate is effective in the treatment of neuroleptic‐induced tardive dyskinesia. This review may provide evidence for its efficacy in the treatment of tardive dyskinesia among patients with schizophrenia and other psychotic disorders. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010501-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010501-sec-0021"></div> <p>To determine the effectiveness of pyridoxal 5 phosphate (vitamin B6, pyridoxine, pyridoxal phosphate) in the treatment of neuroleptic‐induced tardive dyskinesia among patients with schizophrenia and other related psychotic disorders. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010501-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010501-sec-0022"></div> <section id="CD010501-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010501-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials in this review. Quasi‐randomised studies, such as those allocating by alternate days of the week were not eligible for inclusion. We planned that if people were given additional treatments to pyridoxal 5 phosphate, we would only include the data if the adjunct treatment was evenly distributed between groups and it was only pyridoxal 5 phosphate that was randomised. </p> </section> <section id="CD010501-sec-0025"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia or other chronic mental illness, diagnosed by any criteria, irrespective of gender, age or nationality, who: </p> <p> <ol id="CD010501-list-0001"> <li> <p>require the use of antipsychotics for more than three months;</p> </li> <li> <p>developed tardive dyskinesia (diagnosed by any criteria at baseline and at least one other occasion) during antipsychotic treatment; and </p> </li> <li> <p>for whom the dose of antipsychotic medication has been stable for one month or more (the same applied for those free of antipsychotics). </p> </li> </ol> </p> <p>We included only trials where the majority of participants had a diagnosis of schizophrenia.</p> </section> <section id="CD010501-sec-0026"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010501-list-0002"> <li> <p>Pyridoxal 5 phosphate (pyridoxal phosphate, pyridoxine, vitamin B6): any dose or means of administration. </p> </li> <li> <p>Placebo or no intervention.</p> </li> </ol> </p> </section> <section id="CD010501-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD010501-sec-0028"> <h5 class="title">Primary outcomes</h5> <section id="CD010501-sec-0029"> <h6 class="title">1. Clinical efficacy: Clinical efficacy was defined as an improvement in the symptoms of tardive dyskinesia of more than 40%, on any peer‐reviewed scale, after at least four weeks of intervention </h6> </section> </section> <section id="CD010501-sec-0030"> <h5 class="title">Secondary outcomes</h5> <section id="CD010501-sec-0031"> <h6 class="title">1. Global Outcomes</h6> <section id="CD010501-sec-0032"> <p><b>1.1 Death due to suicide or other causes</b></p> </section> <section id="CD010501-sec-0033"> <p><b>1.2 Average endpoint dose of pyridoxal 5 phosphate or vitamin B6</b></p> </section> <section id="CD010501-sec-0034"> <p><b>1.3 Any adverse effects (other than deterioration of tardive dyskinesia symptoms or change in mental state)</b></p> <p><i>1.4 Average time to discontinuation of pyridoxal</i> 5 phosphate<i>and reasons for discontinuation</i> </p> </section> </section> <section id="CD010501-sec-0035"> <h6 class="title"> 2. Tardive dyskinesia</h6> <section id="CD010501-sec-0036"> <p><b>2.1 Deterioration in tardive dyskinesia symptoms</b></p> </section> <section id="CD010501-sec-0037"> <p><b>2.2 Average endpoint tardive dyskinesia score</b></p> </section> </section> <section id="CD010501-sec-0038"> <h6 class="title">3. General mental state changes</h6> <section id="CD010501-sec-0039"> <p><b>3.1 Any deterioration in psychiatric symptoms (such as delusions and hallucinations)</b></p> </section> <section id="CD010501-sec-0040"> <p><b>3.2 Average endpoint psychiatric symptoms score</b></p> </section> </section> <section id="CD010501-sec-0041"> <h6 class="title">4. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD010501-bbs2-0049" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a>) to import data from RevMan 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision‐making. We selected all of our listed outcomes for inclusion in the 'Summary of findings' table. </p> </section> </section> </section> </section> <section id="CD010501-sec-0042"> <h3 class="title">Search methods for identification of studies</h3> <p>No language restriction was applied within the limitations of the search tools.</p> <section id="CD010501-sec-0043"> <h4 class="title">Electronic searches</h4> <p><b>1. Cochrane Schizophrenia Group Trials Register</b> </p> <p>The Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group’s Trials Register (January 2013) using the phrase: </p> <p>[*Pyridoxal* OR *Pyridoxine* OR *P5P* OR *PLP* OR *tardoxal* OR *Vitamin B6* O *Vitamin B 6* R in title, abstract or index terms of REFERENCE, or interventions of STUDY] </p> <p>The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). Incoming trials are assigned to relevant existing or new review titles. </p> </section> <section id="CD010501-sec-0044"> <h4 class="title">Searching other resources</h4> <section id="CD010501-sec-0045"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all identified studies for more studies.</p> </section> <section id="CD010501-sec-0046"> <h5 class="title">2. Personal communication</h5> <p>We contacted the first author of each included study for more information regarding unpublished trials. </p> </section> </section> </section> <section id="CD010501-sec-0047"> <h3 class="title" id="CD010501-sec-0047">Data collection and analysis</h3> <section id="CD010501-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Review authors AOA and OA independently inspected citations from the searches and identified relevant abstracts. A random 20% sample was independently re‐inspected by TMO to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by AOA and OA. Again, a random 20% of reports was re‐inspected by TMO in order to ensure reliable selection.There were no disagreements as to the inclusion or otherwise of any study among the review authors. </p> </section> <section id="CD010501-sec-0049"> <h4 class="title">Data extraction and management</h4> <section id="CD010501-sec-0050"> <h5 class="title">1. Extraction</h5> <p>Review authors AOA and OA extracted data from all included studies. In addition, to ensure reliability, TMO independently extracted data from a random sample of the included studies. Disagreements were discussed, decisions documented and, where necessary, the authors of studies were contacted for clarification. Data presented only in graphs and figures were extracted whenever possible, but were included only if two review authors independently had the same result. We contacted authors of studies through an open‐ended request in order to obtain missing information or for clarification where necessary. </p> <section id="CD010501-sec-0051"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD010501-sec-0052"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD010501-bbs2-0040" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> </section> <section id="CD010501-sec-0053"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data in our analyses. </p> </section> <section id="CD010501-sec-0054"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion:<br/> a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;<br/> b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<a href="./references#CD010501-bbs2-0014" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>); </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We presented and entered all useable change data into analyses. </p> </section> <section id="CD010501-sec-0055"> <h6 class="title">2.7 Direction of graphs</h6> <p>We entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for pyridoxal 5 phosphate.If we had to enter data so the area to the left of the line indicated a favourable outcome for the control group, this was noted in the relevant graphs. </p> </section> </section> </section> <section id="CD010501-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors AOA and OA independently assessed risk of bias by using criteria described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010501-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) to assess trial quality. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If inadequate details of randomisation and other characteristics of trials were provided, we contacted the authors of the studies in order to obtain further information. </p> <p>The level of risk of bias was noted in both the text of the review and in the '<a href="./full#CD010501-tbl-0001">summary of findings Table for the main comparison</a> </p> </section> <section id="CD010501-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010501-sec-0058"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD010501-bbs2-0020" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD010501-bbs2-0027" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat to benefit/harm (NNTB/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD010501-bbs2-0035" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the '<a href="./full#CD010501-tbl-0001">summary of findings Table for the main comparison</a>, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD010501-sec-0059"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated the mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, where scales of very considerable similarity were used, we presumed there was a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD010501-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <section id="CD010501-sec-0061"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Divine-1992" target="_blank">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Bland-1997" target="_blank">Bland 1997</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Gulliford-1999" target="_blank">Gulliford 1999</a>). </p> <p>We did not find any cluster trials in this search. If we had, we would have employed the methods below. </p> <p>Where clustering is not accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if cluster trials are included, we will seek to contact the first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Gulliford-1999" target="_blank">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>We sought statistical advice and were advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Donner-2002" target="_blank">Donner 2002</a>). If the ICC is not reported, it will be assumed to be 0.1 (<a href="http://archie.cochrane.org/sections/documents/view?version=z1304200633452892791393032528936%26format=REVMAN#REF-Ukoumunne-1999" target="_blank">Ukoumunne 1999</a>). </p> <p>Where cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD010501-sec-0062"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD010501-bbs2-0028" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data from the first phase of cross‐over studies. </p> </section> </section> <section id="CD010501-sec-0063"> <h4 class="title">Dealing with missing data</h4> <section id="CD010501-sec-0064"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD010501-bbs2-0056" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). For any particular outcome, where more than 50% of data was unaccounted for, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table by down‐rating quality. Finally, we also downgraded quality within the '<a href="./full#CD010501-tbl-0001">summary of findings Table for the main comparison</a> where loss was 25% to 50% in total. </p> </section> <section id="CD010501-sec-0065"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stayed in the study ‐ in that particular arm of the trial ‐ was used for those who did not. </p> </section> <section id="CD010501-sec-0066"> <h5 class="title">3. Continuous</h5> <section id="CD010501-sec-0067"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we reproduced these. </p> </section> <section id="CD010501-sec-0068"> <h6 class="title">3.2 Standard deviations</h6> <p>When only the standard error (SE) was reported, SDs were calculated by the formula SD = SE * square root (n). </p> </section> <section id="CD010501-sec-0069"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed effects models for repeated measurements (MMRM) have become more of a standard. While the latter methods seem to somewhat better than LOCF (<a href="https://archie.cochrane.org/sections/documents/view?version=z1503041621435423288359801464857%26format=REVMAN#REF-Leon-2006" target="_blank">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, we prefer to use the more sophisticated approaches. E.g. MMRM or multiple‐imputation is preferred to LOCF and completer analyses would only be presented if some kind of ITT data are not available at all. Moreover, we addressed this issue in the item "incomplete outcome data" of the risk of bias tool. </p> </section> </section> </section> <section id="CD010501-sec-0070"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD010501-sec-0071"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. </p> </section> <section id="CD010501-sec-0072"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. </p> </section> <section id="CD010501-sec-0073"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD010501-sec-0074"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD010501-sec-0075"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>Heterogeneity between studies was investigated by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> 'P' value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD010501-bbs2-0032" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD010501-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Had substantial levels of heterogeneity been found in the primary outcome, we would have explored reasons for heterogeneity (<a href="#CD010501-sec-0079">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD010501-sec-0076"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD010501-sec-0077"> <h5 class="title">Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD010501-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We tried to locate protocols of the included randomised trials. Had protocols been available, outcomes in the protocol and in the published report would have been compared. Consequently, outcomes listed in the methods section of the trial report were compared with actually reported results. </p> </section> </section> <section id="CD010501-sec-0078"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We therefore chose to use a fixed‐effect method for all analyses. </p> </section> <section id="CD010501-sec-0079"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD010501-sec-0080"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD010501-sec-0081"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not undertake any subgroup analyses due to lack of data.</p> </section> <section id="CD010501-sec-0082"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We undertook this review and provided an overview of the effects of pyridoxal 5 phosphate for people with neuroleptic‐induced tardive dyskinesia in general. </p> </section> </section> <section id="CD010501-sec-0083"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We would have reported inconsistency where it was high. First, we would have investigated whether data had been entered correctly. Second, where data were correct, the graphs would have been visually inspected and outlying studies were removed to see if homogeneity was restored. </p> <p>We decided that if unanticipated clinical or methodological heterogeneity were obvious, we would simply state hypotheses regarding these for future reviews or versions of this review. We did not plan to undertake analyses relating to these. </p> </section> </section> <section id="CD010501-sec-0084"> <h4 class="title">Sensitivity analysis</h4> <section id="CD010501-sec-0085"> <h5 class="title">1. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD010501-sec-0063">Dealing with missing data</a>), we compared the findings of the primary outcomes when we used our assumption/s and used data only from people who completed the study to that point. When there was a substantial difference, we reported the results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD010501-sec-0086"> <h5 class="title">2. Risk of bias</h5> <p>If we had found trials with a high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available) allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome, we would have analysed the effects of excluding trials that were judged to be at high risk of bias. If the exclusion of trials at high risk of bias does not substantially alter the direction of effect or the precision of the effect estimates, then data from these trials would have been included in the analysis. </p> </section> <section id="CD010501-sec-0087"> <h5 class="title">3. Fixed and random effects</h5> <p>All data were synthesised using a fixed‐effect model.</p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010501-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010501-sec-0088"></div> <section id="CD010501-sec-0089"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD010501-sec-0146" title="">Characteristics of included studies</a>; <a href="./references#CD010501-sec-0147" title="">Characteristics of excluded studies</a> </p> <section id="CD010501-sec-0090"> <h4 class="title">Results of the search</h4> <p>Using the search criteria, the electronic database search carried out in January 2013 yielded 12 trials No additional relevant references were identified from the reference lists of the published trials. See <a href="#CD010501-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010501-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010501-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010501-sec-0091"> <h4 class="title">Included studies</h4> <p>The review included three randomised, double blind, controlled studies published in 2001, 2003 and 2007 (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). For more details, see <a href="./references#CD010501-sec-0146" title="">Characteristics of included studies</a> and the accompanying 'Risk of bias' tables. </p> <section id="CD010501-sec-0092"> <h5 class="title">1. Setting</h5> <p>The three studies included in this review were conducted at the mental health unit of Be'er Sheva Mental Health Centre in Israel. </p> </section> <section id="CD010501-sec-0093"> <h5 class="title">2. Length of Trials</h5> <p>All three included studies had cross‐over designs. The included trials varied in duration; from nine weeks (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>), to 26 weeks (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>), including a wash‐out period of either one week (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) or two weeks (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). </p> </section> <section id="CD010501-sec-0094"> <h5 class="title">3. Participants</h5> <p>There were a total of 80 participants in the included trials. Participants in all the studies were inpatients of a mental health facility with diagnoses of schizophrenia and schizoaffective disorders. The diagnoses were either based on DSM IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for schizophrenia or schizoaffective disorders (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>) or ICD‐10 (International Statistical Classification of Diseases, 10th Revision) criteria (<a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>). One of the studies did not specify a diagnostic criteria (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>). </p> <p>In total there were more women (n = 44) than men (n = 36) in the included studies. Participants' ages ranged from 18 to 60 years (<a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) to 28 to 71 years (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>) and 20 to 66 years (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). </p> </section> <section id="CD010501-sec-0095"> <h5 class="title">4. Trial Size</h5> <p>The overall trial size in the three included studies was small. The total number of participants in each trial ranged from 15 each in <a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a> and <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a> to 50 in <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>. </p> </section> <section id="CD010501-sec-0096"> <h5 class="title">5. Interventions</h5> <p>Participants in the three included studies either received vitamin B6 or placebo, in addition to their ongoing medication regimens, which remained unchanged throughout the study durations. The maximal daily dose of vitamin B6 used in the included studies ranged from 400 mg (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) to 1200 mg (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). </p> </section> <section id="CD010501-sec-0097"> <h5 class="title">6. Outcomes</h5> <p>Details of scales providing useable data are described below:</p> <p><b>6.1 Tardive dyskinesia</b> </p> <p>6.1.1. Extrapyramidal Symptom Rating Scale (ESRS) ‐ <a href="./references#CD010501-bbs2-0025" title="ChouinardG , MargoleseHC . Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research2005;76(2‐3):247‐65. ">Chouinard 2005</a> </p> <p>The ESRS is a measure of the severity of movement disorders in patients with schizophrenia taking antipsychotic medications. The ESRS measures four types of drug‐induced movement disorders viz: parkinsonism, akathisia, dystonia and tardive dyskinesia. Each of these movement disorders can be scored from normal (score of zero) to extremely severe (score of six), according to the symptom severity. </p> <p>ESRS was used to assess the severity of tardive dyskinesia symptoms and clinical efficacy of the interventions by the studies included in this review (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>, <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>). The assessments were performed at baseline, repeated either every week (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>), or at least every two weeks (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). A 20% reduction in ESRS scores from baseline to week four (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) or week 12 (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>) was taken to represent no clinical response, 21% to 40% as minimal improvement, 41% to 60% as moderate improvement, and more than 61% as marked improvement. </p> <p><b>6.2 General mental state changes</b> </p> <p>6.2.1 Positive And Negative Symptoms Scale (PANSS) ‐ <a href="./references#CD010501-bbs2-0037" title="KaySR , FiszbeinA , OplerLA . The positive and negative syndrome scale (PANSS) forschizophrenia. Schizophrenia Bulletin1987;13:261‐76. ">Kay 1987</a> </p> <p>The PANSS is a 30‐item seven‐point rating scale divided into positive (seven items), negative (seven items) and general psychopathology (16 items) sub‐scales. It was designed to assess the clinical symptoms of schizophrenia by a clinician rater, using a semi‐structured interview. Each item on the PANSS is scored on a seven‐point Likert scale ranging from one to seven and the rating can generally be completed in 30 to 40 minutes. The PANSS can reliably be administered to assess symptoms improvement and exacerbations. </p> <p>PANSS was used in one of the included trials (<a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) to assess the severity of psychiatric symptoms among participants taking vitamin B6 and placebo. </p> </section> </section> <section id="CD010501-sec-0098"> <h4 class="title">Excluded studies</h4> <p>Overall, eight studies were excluded from the review. Of these four randomised double blind controlled studies reported insufficient data and some data obtained following communication with study authors were not usable (<a href="./references#CD010501-bbs2-0005" title="LernerV , MiodownikC , KaptsanA , CohenH , LoewentalU , KotlerM . Double‐blind evaluation of Vitamin B6 vs Placebo in treatment of tardive dyskinesia. European Neuropsychopharmacology. 1999; Vol. 9:S369. ">Lerner 1999</a>; <a href="./references#CD010501-bbs2-0006" title="LernerV , CohenH . A double‐blind, randomised, placebo‐controlled, crossover study of the effects of vitamin B6 in 50 in‐patients with tardive dyskinesia. Stanley Foundation Research Institute2002. ">Lerner 2002</a>; <a href="./references#CD010501-bbs2-0007" title="LernerV . Vitamin B‐sub‐6. The experience in treating psychotic symptoms and psychotropic drug‐indced movement disorders. In: PletsonJE editor(s). Psychology and Schizophrenia. Hauppauge, NY, US: Nova Science Publishers, 2007:105‐38. ">Lerner 2007a</a>; <a href="./references#CD010501-bbs2-0008" title="LernerV . Vitamin B6 for tardive movement disorder. Stanley Foundation Research Programs2009. ">Lerner 2009</a>). Two studies did not use vitamin B6/pyridoxal phosphate (<a href="./references#CD010501-bbs2-0011" title="XiaoG , JinY , LuoX . The effect of huangqi injection in the treatment of tardive neuropathy caused by acute organophosphorus insecticide poisoning. Herald of Medicine2002;21(9):558‐60. ">Xiao 2002</a>, <a href="./references#CD010501-bbs2-0004" title="GreenbergWM . A 12‐week, double‐blind, augmentation study of the effects of folic acid, B‐12, and pyridoxine in lowering homocysteine levels and treating psychopathology and cognitive deficits in schizophrenia. Stanley Foundation Research Programs2003. ">Greenberg 2003</a>), while two studies had participants with diagnoses other than schizophrenia/schizoaffective disorders (<a href="./references#CD010501-bbs2-0010" title="VenegasF , SinningO , MillanA , MirandaC , RoblesG , AstudilloA , et al. Pyridoxine for drug induced dyskinesia. A placebo‐ controlled randomised cross‐over trial [Piridoxina en el manejo de Disquinesias Tardías. Un estudio placebo controlado, randomizado,doble ciego y cruzado]. Revista Chilena de Neuropsiquiatrica2006;44(1):9‐14. ">Venegas 2006</a>, <a href="./references#CD010501-bbs2-0009" title="NCT00202280 . Efficacy of treating first episode psychosis with folic acid, vitamin B12 and B6 in addition to antipsychotic medication. http://www.clinicaltrials.gov./ct2/show/NCT00202280?term=NCT00202280&amp;rank=1. ">NCT00202280</a>). </p> <section id="CD010501-sec-0099"> <h5 class="title">Ongoing studies</h5> <p>One study was still ongoing as at July 2013 (<a href="./references#CD010501-bbs2-0012" title="NCT00917293 . Safety and efficacy of avastrem (pyridoxal 5' ‐phosphate) in the treatment of tardive dyskinesia. http://www.clinicaltrials.gov2009. ">NCT00917293</a>). </p> </section> </section> </section> <section id="CD010501-sec-0100"> <h3 class="title">Risk of bias in included studies</h3> <p>For a graphical overview please see <a href="#CD010501-fig-0002">Figure 2</a> and <a href="#CD010501-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010501-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010501-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010501-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010501-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010501-sec-0101"> <h4 class="title">Allocation</h4> <p>The included studies were described as randomised placebo‐controlled studies. However, none of the included studies described a specific method of randomisation or of allocation concealment, making allocation bias to be unclear. </p> </section> <section id="CD010501-sec-0102"> <h4 class="title">Blinding</h4> <p>Although the included studies were described as double‐blind, placebo‐controlled studies, none explicitly described how this was undertaken and how the investigators, participants and outcome raters were blinded. </p> </section> <section id="CD010501-sec-0103"> <h4 class="title">Incomplete outcome data</h4> <p>All participants randomised at the beginning of the three studies included were accounted for, making their attrition bias to be low. </p> </section> <section id="CD010501-sec-0104"> <h4 class="title">Selective reporting</h4> <p>Two of the included studies (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) accounted for all outcomes at the study completion. <a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a> did not account for all outcomes with the specific number of participants who showed none, minimal, moderate or marked improvement in their tardive dyskinesia symptoms from both arms of the study not reported by this study, making the risk of bias to be high. Specific outcomes such as the number of participants who withdrew due to side effects were not accounted for by the second included study (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>), thus making the risk of bias to be high. Also, due to inadequate reporting, it was difficult to ascertain from which arm of the study the numbers of participants who left the study early came from. For <a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>, using a flow chart would have been an appropriate measure to accurately reflect these numbers. </p> </section> <section id="CD010501-sec-0105"> <h4 class="title">Other potential sources of bias</h4> <p><b>1. Funding</b> </p> <p>Only one of the included studies reported financial sponsorship from a research institution (<a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). It was not clear if the other studies (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) received funding from any sponsor. </p> <p><b>2. Plasma level of pyridoxal 5 phosphate</b> </p> <p>The three studies included in this review did not mention who measured the plasma level of pyridoxal 5 phosphate and did not describe the extent to which the raters were independent. </p> </section> </section> <section id="CD010501-sec-0106"> <h3 class="title" id="CD010501-sec-0106">Effects of interventions</h3> <p>See: <a href="./full#CD010501-tbl-0001"><b>Summary of findings for the main comparison</b> Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</a> </p> <p>Although three studies were included in this review, in some instances the data reported by <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a> were not useable, hence only outcomes from the other two included studies (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>) were reported. </p> <section id="CD010501-sec-0107"> <h4 class="title">1. COMPARISON: Pyridoxal 5 phosphate (vitamin B6) versus placebo</h4> <section id="CD010501-sec-0108"> <h5 class="title">1.1 Clinical efficacy (Extrapyramidal Symptom Rating Scale (ESRS), high = worse)</h5> <section id="CD010501-sec-0109"> <h6 class="title">1.1.1 Improvement in tardive dyskinesia symptoms from baseline</h6> <p><a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a> reported a 68.6% (SD 23%) reduction in ESRS symptoms from baseline to week four among participants taking vitamin B6, indicating marked improvement. In <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>, 15 (65%) of the 23 participants treated with vitamin B6 demonstrated &gt; 40% reduction in their ESRS scores from baseline to week 12, indicating moderate to marked improvement. No clinical response to placebo was observed among participants in both studies, implying that placebo failed to produce not more than 20% reduction in ESRS scores from baseline to either week four or week 12 (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>).The pooled summary result showed that pyridoxal 5 phosphate was clinically efficacious compared to placebo in reducing tardive dyskinesia symptoms (2 RCTs, n = 65, risk ratio (RR) 19.97, 95% confidence interval (CI) 2.87 to 139.19). </p> </section> </section> <section id="CD010501-sec-0110"> <h5 class="title">1.2 Global</h5> <section id="CD010501-sec-0111"> <h6 class="title">1.2.1 Death due to suicide or other causes</h6> <p>None of the included studies reported any data on this outcome.</p> </section> <section id="CD010501-sec-0112"> <h6 class="title">1.2.2 Average endpoint dose of pyridoxal 5 phosphate</h6> <p><a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a> and <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a> reported an endpoint vitamin B6 dose of 400 mg daily, while <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a> reported an endpoint vitamin B6 dose of 1200 mg daily. </p> </section> <section id="CD010501-sec-0113"> <h6 class="title">1.2.3 Other adverse effects than tardive dyskinesia</h6> <p>Adverse effects other than the deterioration of tardive dyskinesia symptoms were reported in two of the included studies (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>). There was no significant difference in adverse effects reported by participants on pyridoxal 5 phosphate when compared with those on placebo (2 RCTs, n=65, RR 3.97, 95% CI 0.20 to 78.59). </p> </section> <section id="CD010501-sec-0114"> <h6 class="title">1.2.4 Discontinuation of treatment</h6> <p><a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a> reported 5 participants on pyridoxal 5 phosphate who discontinued their medications because they were unwilling to take additional medications. None of the participants in <a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a> study discontinued their treatment. The pooled summary estimate did not show any significant difference between participants on pyridoxal 5 phosphate who discontinued their medications compared to those on placebo. (2 RCTs, n= 65, RR 8.72, 95% CI 0.51 to 149.75). The time to discontinuation of pyridoxal 5 phosphate was not stated. </p> </section> </section> <section id="CD010501-sec-0115"> <h5 class="title">1.3 Tardive dyskinesia (ESRS, high = worse)</h5> <section id="CD010501-sec-0116"> <h6 class="title">1.3.1 Deterioration in tardive dyskinesia symptoms</h6> <p><a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a> reported deterioration of tardive dyskinesia symptoms in two study participants on placebo. However, the pooled summary did not show any significant difference in deterioration of tardive dyskinesia symptoms in those on placebo compared to those on pyridoxal 5 phosphate (2 RCTS, n = 65, RR 0.16, 95% CI 0.01 to 3.14). </p> </section> <section id="CD010501-sec-0117"> <h6 class="title">1.3.2 Average endpoint ESRS tardive dyskinesia score</h6> <p>The pooled summary result from two of the included studies (<a href="./references#CD010501-bbs2-0001" title="LernerV , MiodownikC , KaptsanA , CohenH , MatarM , LoewenthalU , et al. Vitamin B6 in the treatment of tardive dyskinesia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(9):1511‐4. ">Lerner 2001</a>; <a href="./references#CD010501-bbs2-0002" title="LernerV , MiodownikC , KapstanA , BersudskyY , LibovI , SelaB‐M , et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychiatry2007;68(11):1648‐54. ">Lerner 2007</a>) showed a beneficial effect of pyridoxal 5 phosphate when compared with placebo (2 RCTs, n = 60, mean difference (MD) ‐4.07, 95% CI ‐6.36 to ‐1.79). <a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a> reported the endpoint ESRS tardive dyskinesia scores on an unscaled graph, thereby making the data unable to be used. </p> </section> </section> <section id="CD010501-sec-0118"> <h5 class="title">1.4 General mental state changes (Positive and Negative Symptoms Scale (PANSS), high = worse) </h5> <section id="CD010501-sec-0119"> <h6 class="title">1.4.1 Deterioration in psychiatric symptoms (e.g. hallucinations and delusions)</h6> <p>None of the included studies reported data on this outcome</p> </section> <section id="CD010501-sec-0120"> <h6 class="title">1.4.2 Average endpoint PANSS psychiatric symptoms score</h6> <p>One of the included studies (<a href="./references#CD010501-bbs2-0003" title="MiodownikC , CohenH , KotlerM , LernerV . Vitamin B6 ad‐on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders. Harefuah2003;142(8‐9):592‐6, 647. ">Miodownik 2003</a>) reported average endpoint psychiatric symptoms scores for participants on vitamin B6 and placebo, assessed with the PANSS. The pooled summary result for positive symptoms of schizophrenia did not show any significant differences between participants on vitamin B6 compared to those on placebo (1 RCT, n = 15, MD ‐1.50, CI ‐4.80 to 1.80). The pooled summary estimate showed no significant improvements in negative symptoms of schizophrenia (such as social withdrawal, lack of motivation) among participants on vitamin B6 compared to those on placebo (1 RCT, n = 15, MD ‐1.10, 95% CI ‐5.92 to 3.72). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010501-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010501-sec-0121"></div> <section id="CD010501-sec-0122"> <h3 class="title" id="CD010501-sec-0122">Summary of main results</h3> <p>The aim of this review was to determine the effectiveness of pyridoxal 5 phosphate (vitamin B6 or Pyridoxine or Pyridoxal phosphate) in the treatment of neuroleptic‐induced tardive dyskinesia among patients with schizophrenia and other related psychotic disorders. The review included all relevant randomised controlled trials obtained from the Cochrane Schizophrenia Group's Trial Register as at January 2013. </p> <p>However, it should be noted that there are few studies included in this review, the size of the studies is small and all outcomes of interest were rated as 'low' quality evidence (also see <a href="./full#CD010501-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Evidence from the three available studies in this review showed that pyridoxal 5 phosphate may be superior to placebo in reducing tardive dyskinesia symptoms among patients with schizophrenia on antipsychotic medications. The number of participants on pyridoxal 5 phosphate who had &gt; 40% improvement in their tardive dyskinesia symptoms at the end of the study was significantly higher than those on placebo. However, its effect for other outcomes of interest are unclear. There was no significant difference in other adverse effects experienced by those on pyridoxal 5 phosphate compared to those on placebo and pyridoxal 5 phosphate did not cause significant worsening or improvement of psychiatric symptoms among study participants. </p> </section> <section id="CD010501-sec-0123"> <h3 class="title" id="CD010501-sec-0123">Overall completeness and applicability of evidence</h3> <p>The sample size of trials and the number of participants included in this review are small, furthermore the duration of follow‐up is short, thereby making generalisation of the evidence obtained on the efficacy of pyridoxal 5 phosphate compared with placebo in the treatment of tardive dyskinesia difficult and limited. </p> </section> <section id="CD010501-sec-0124"> <h3 class="title" id="CD010501-sec-0124">Quality of the evidence</h3> <p>There is a dearth of studies on the effectiveness of pyridoxal 5 phosphate in the treatment of tardive dyskinesia. The quality of evidence for the efficacy of pyridoxal 5 phosphate provided by the studies included in this review is low. This review evaluated evidence from three studies with a total of 80 participants, assessed over a period of nine to 26 weeks in a cross‐over study design. The quality of evidence from future studies could be significantly improved with larger sample sizes to increase their power, as well as longer duration of follow‐up for study participants, especially since tardive dyskinesia symptoms often run a fluctuating course (<a href="./references#CD010501-bbs2-0015" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC1992. ">APA 1992</a>). In addition, adherence to guidelines for reporting randomised controlled trials that emphasise the explicit description of the processes of randomisation, allocation concealment and blinding etc could help improve the quality of future studies on this subject. Such reporting guidelines include the CONSORT (Consolidated Standards of Reporting Trials) statement (<a href="./references#CD010501-bbs2-0043" title="MoherD , SchulzKF , AltmanD , CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285:1987‐91. ">Moher 2001</a>). The evidence provided by the studies included in this review should be interpreted in the light of the limitations mentioned above. </p> </section> <section id="CD010501-sec-0125"> <h3 class="title" id="CD010501-sec-0125">Potential biases in the review process</h3> <p>No known potential biases in the review process were identified by the authors of this review. </p> </section> <section id="CD010501-sec-0126"> <h3 class="title" id="CD010501-sec-0126">Agreements and disagreements with other studies or reviews</h3> <p>A recent systematic review presented as a conference proceeding, comprising 105 randomised controlled trials which assessed the evidence for various natural medicines in reducing antipsychotics side effects in schizophrenia, reported vitamin B6 to be effective in reducing medication‐induced tardive dyskinesia (<a href="./references#CD010501-bbs2-0034" title="HoendersR , Bartels‐VelthuisA , VollbehrN , BruggemanR , KnechteringR , deJongJ . Natural medicines in schizophrenia: A systematic review. Journal of Alternative and Complementary Medicine. 2014; Vol. 20, issue 5:A79‐80. ">Hoenders 2014</a>). However, no quantitative data were reported in the abstract of the systematic review and no full text of the review is available yet. To the best knowledge of the authors of this review, there are no other reviews to which the findings of this review could be compared. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010501-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010501-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010501-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010501-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 1 Global: Clinical efficacy ‐ significant reduction in ESRS scores from baseline." data-id="CD010501-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 1 Global: Clinical efficacy ‐ significant reduction in ESRS scores from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0005"> <p> <div class="table" id="CD010501-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lerner 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lerner 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1200 mg daily</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miodownik 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400 mg daily</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 2 Global 1. Average endpoint dose of pyridoxal 5 phosphate. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0005">Navigate to figure in review</a></div> </div> <div class="figure" id="CD010501-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 3 Global: 2. Other adverse effects than tardive dyskinesia." data-id="CD010501-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 3 Global: 2. Other adverse effects than tardive dyskinesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 4 Global: 3. Discontinuation of Vitamin B6." data-id="CD010501-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 4 Global: 3. Discontinuation of Vitamin B6. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 5 Tardive dyskinesia: 1. Deterioration in tardive dyskinesia symptoms." data-id="CD010501-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 5 Tardive dyskinesia: 1. Deterioration in tardive dyskinesia symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 6 Tardive dyskinesia: 2. Average endpoint ESRS tardive dyskinesia scores." data-id="CD010501-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 6 Tardive dyskinesia: 2. Average endpoint ESRS tardive dyskinesia scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 7 General Mental State: Average endpoint positive psychiatric symptoms score." data-id="CD010501-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 7 General Mental State: Average endpoint positive psychiatric symptoms score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010501-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/urn:x-wiley:14651858:media:CD010501:CD010501-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_t/tCD010501-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 8 General mental state: Average endpoint negative psychiatric symptoms score." data-id="CD010501-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Pyridoxal 5 phosphate (Vitamin B6) versus placebo, Outcome 8 General mental state: Average endpoint negative psychiatric symptoms score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/media/CDSR/CD010501/image_n/nCD010501-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010501-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Possible design for a future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blinding: double ‐ described and tested.<br/> Duration: long term.<br/> Setting: Inpatients and outpatients </p> <p>Design: Single phase, longer study duration.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with schizophrenia or schizophrenia‐like disorder.<br/> N = Sample size obtained through power calculation.<br/> Age: any<br/> Sex: both </p> <p>History: History of tardive dyskinesia, fulfilling diagnostic criteria for tardive dyskinesia, stable on antipsychotic medication for at least 3 months. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.Pyridoxal Phosphate (vitamin B6), any dose</p> <p>2. Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia scores measured using AIMS (primary outcome)</p> <p>Deterioration of tardive dyskinesia symptoms</p> <p>Any other adverse effects</p> <p>Discontinuation of pyridoxal phosphate (with reasons)</p> <p>Psychiatric symptoms score using a standardised rating scale (PANSS, BPRS)</p> <p>Pyridoxal phosphate dose</p> <p>Plasma pyridoxal phosphate level</p> <p>Quality of life</p> <p>Satisfaction with care</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>AIMS: Abnormal Involuntary Movement Scale<br/> BPRS: Brief Psychiatric Rating Scale<br/> PANSS: Positve and Negative Scale of Schizophrenia </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Possible design for a future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010501-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with neuroleptic‐induced tardive dyskinesia<br/> <b>Settings:</b> Inpatients<br/> <b>Intervention:</b> Pyridoxal 5 phosphate (vitamin B6)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Pyridoxal 5 phosphate (vitamin B6) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical efficacy ‐ improvement (&gt; 40%) in ESRS scores from baseline</b> <br/> ESRS<sup>1</sup> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 19.97</b> <br/> (2.87 to 139.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global: Other adverse effects than tardive dyskinesia</b> <br/> Self‐report by participants<br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.97</b> <br/> (0.2 to 78.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global: Discontinuation of Vitamin B6</b> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 8.72</b> <br/> (0.51 to 149.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Tardive dyskinesia: Deterioration in tardive dyskinesia symptoms</b> <br/> ESRS<sup>1</sup> <br/> Follow‐up: mean 17.5 weeks<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.16</b> <br/> (0.01 to 3.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (1 to 217) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (0 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Positive psychiatric symptom score</b> <br/> PANSS<sup>5</sup>. Scale from: 7 to 49.<br/> Follow‐up: 9 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: positive psychiatric symptom score in the control groups was<br/> <b>15.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: positive psychiatric symptom score in the intervention groups was<br/> <b>1.50 lower</b> <br/> (4.80 lower to 1.80 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General mental state: Negative psychiatric symptoms</b> <br/> PANSS<sup>5</sup>. Scale from: 7 to 49.<br/> Follow‐up: 9 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: negative psychiatric symptoms in the control groups was<br/> <b>14.6</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean general mental state: negative psychiatric symptoms in the intervention groups was<br/> <b>1.10 lower</b> <br/> (5.92 lower to 3.72 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Extrapyramidal Symptom Rating Scale (high scores = worse)<br/> <sup>2</sup> Study duration: 9 weeks and 26 weeks respectively for the two included studies<br/> <sup>3</sup> Adequate description of randomisation methods was not provided. Methods for allocation concealment and blinding were not described.<br/> <sup>4</sup> The included studies have small sample sizes<br/> <sup>5</sup> Positive and Negative Symptoms Scale (high scores = worse)<br/> <sup>6</sup> Study has a small sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pyridoxal 5 phosphate (vitamin B6) compared with Placebo for neuroleptic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/full#CD010501-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010501-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pyridoxal 5 phosphate (Vitamin B6) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global: Clinical efficacy ‐ significant reduction in ESRS scores from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.97 [2.87, 139.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global 1. Average endpoint dose of pyridoxal 5 phosphate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global: 2. Other adverse effects than tardive dyskinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [0.20, 78.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global: 3. Discontinuation of Vitamin B6 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.72 [0.51, 149.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Tardive dyskinesia: 1. Deterioration in tardive dyskinesia symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Tardive dyskinesia: 2. Average endpoint ESRS tardive dyskinesia scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.07 [‐6.36, ‐1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 General Mental State: Average endpoint positive psychiatric symptoms score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐4.80, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 General mental state: Average endpoint negative psychiatric symptoms score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐5.92, 3.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pyridoxal 5 phosphate (Vitamin B6) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010501.pub2/references#CD010501-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010501.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010501-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010501-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010501-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010501-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD010501-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010501\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010501\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010501\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010501\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010501\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010501.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010501.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010501.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010501.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010501.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720122494"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010501.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720122497"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010501.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df9759d179377',t:'MTc0MDcyMDEyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 